Prof. Dr. Michael Laxy, Quelle: genehmigt

Prof. Dr. Michael Laxy
Leiter der AG 2

Telefon: +49 89 3187-4175
Fax: +49 89 3187-3375
Geb./Raum: 96/03



  • 2012-2016: Ph.D. Public Health & Epidemiology, Ludwig Maximilians Universität München
  • 2013-2015: M.Sc. Clinical and Genetic Epidemiology, Ludwig Maximilians Universität München
  • 2010-2012: Master of Public Health (MPH), Ludwig Maximilians Universität München
  • 2006-2010: B.A. Sportwissenschaften, Technische Universität München
  • 2008-2015: Grundstudium Wirtschaftswissenschaften, Fern-Universität Hagen


Berufliche Stationen

  • Seit 2020: Professor für Public Health und Prävention, Technische Universität München
  • Seit 2019: Adjunct Professor, Rollins School of Public Health, Emory University
  • Seit 2017: Leiter Arbeitsgruppe 2, IGM, Helmholtz Zentrum München
  • 2017-2018: Harkness Fellow for Health Care Policy and Practice, CDC, Atlanta, GA
  • 2015-2017: Wissenschaftlicher Mitarbeiter, IGM, Helmholtz Zentrum München
  • 2015-2017: Gastwissenschaftler, MRC Epidemiology Unit, University of Cambridge
  • 2012-2015: Doktorand , IGM, Helmholtz Zentrum München
  • 2011: Gastwissenschaftler, Department of Populations Health Sciences, University of Wisconsin, Madison


Forschungsinteressen und Arbeitsschwerpunkte



  • Gesundheitsökonomische Evaluation von Präventions- und Managementstrategien
  • Public Health und verhaltensökonomische Aspekte bei Adipositas und Diabetes


Ausgewählte Publikationen


Laxy, M., Schöning, V.M., Kurz, C., Holle, R., Peters, A., Meisinger, C., Rathmann, W., Mühlenbruch, K., Kähm, K.: Performance of the UKPDS outcomes model V2.0 for predicting death and cardiovascular events in patients with type 2 diabetes of a German population-based cohort. Pharmacoeconomics 2019 Jul 27

Kurz, C., Rehm, M., Holle, R., Laxy, M., Teuner, C.M., Schwarzkopf, L.: The effect of bariatric surgery on health care utilization: A synthetic control approach using Bayesian structural time series. Health Economics 2019 Sep 5

Laxy M., Kähm K.: Health economic evaluation of diabetes prevention and management strategies. Der Diabetologe (2019) 15: 514.

Kähm, K., Laxy, M., Schneider, U., Rogowski, W.H., Lhachimi, S.K., Holle, R.: Healthcare costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care. 2018 May;41(5):971-978

Laxy, M., Wilson, E., Boothby, C., Griffin, S.: Incremental costs and cost-effectiveness of intensive treatment in patients with screen-detected type 2 diabetes in the ADDITION-UK trial: An update with empirical trial-based cost data. Value in Health 2017 20(10):1288-1298

Ulrich, S., Holle, R., Wacker, M., Stark R., Icks, A., Thorand, B., Peters, A., Laxy, M.: The Cost Burden of Type 2 Diabetes – Results from the Population-based KORA Studies in Southern Germany. BMJ Open 6 (11), e012527 (2016)

Laxy, M., Malecki, K.C., Givens, M.L., Walsh, M.C., Nieto, F.J.: The association between neighborhood economic hardship, the retail food environment, fast food intake and obesity: Findings from the Survey of the Health of Wisconsin. BMC Public Health 15:237 (2015)

Laxy, M., Mielck, A., Hunger, M., Schunk, M., Meisinger, C., Rückert, I.M., Rathmann, W., Holle, R.: The association between patient-reported self-management behavior, intermediate outcomes and mortality in type 2 diabetes patients: Results from the KORA-A study. Diabetes Care 37:1604-12 (2014)